Bob Lechleider
Technik-/Wissenschafts-/F&E-Leiter bei IMMUNOME, INC.
Aktive Positionen von Bob Lechleider
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| IMMUNOME, INC. | Technik-/Wissenschafts-/F&E-Leiter | 19.10.2023 | - |
Karriereverlauf von Bob Lechleider
Ehemalige bekannte Positionen von Bob Lechleider
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
OncoResponse, Inc.
 OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA. | Technik-/Wissenschafts-/F&E-Leiter | 01.04.2020 | 01.10.2023 |
| SEAGEN INC. | Technik-/Wissenschafts-/F&E-Leiter | - | 01.01.2023 |
Ausbildung von Bob Lechleider
| Princeton University | Undergraduate Degree |
| University of Illinois College of Medicine | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 6 |
Operativ
| Chief Tech/Sci/R&D Officer | 3 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Sektoral
| Health Technology | 4 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| IMMUNOME, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
OncoResponse, Inc.
OncoResponse, Inc. BiotechnologyHealth Technology OncoResponse, Inc. discovers cancer immunotherapies by interrogating the human immune system. The firm identifies elite responders to immunotherapy and screens the adaptive immune system to discover antibodies with reactivity. The company was founded by Clifford J. Stocks, Kristine Swiderek and Steven H. Gillis in 2015 and is headquartered in Seattle, WA. | Health Technology |
Seagen Inc.
 Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
- Börse
- Insiders
- Bob Lechleider
- Erfahrung
